TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with histologically- or cytologically-confirmed metastatic adenocarcinoma of the colon and/or rectum.~* Measurable disease according to modified RECIST guidelines.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.~* Paraffin-embedded tissue or unstained tumour slides from primary or metastatic tumour available for central lab analysis.~* Adequate haematologic, renal, hepatic and metabolic function.~Exclusion Criteria:~* Central nervous system metastases.~* Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months prior to initiating study treatment.~* Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (e.g. cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g. erlotinib).~* Prior radiotherapy within 14 days prior to screening, and for which all signs of early radiological toxicity have not abated.~* Significant cardiovascular disease including unstable angina or myocardial infarction within six months before initiating study treatment or a history of ventricular arrhythmia.~* History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest computed tomography (CT scan.~* Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as \> 4 loose stools per day).~* History of Gilbert's syndrome or dihydropyrimidine deficiency.~* Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection.~* Any investigational agent within 30 days before initiation of study treatment.~* Must not have had a major surgical procedure within 28 days prior to initiation of study treatment.~* Subject who is pregnant or breast-feeding.~* Woman or man of childbearing potential not consenting to use adequate contraceptive precautions during the course of the study and for six months after the last study drug administration for women, and one month for men.~  * Other protocol specified criteria and specific details may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab plus FOLFIRI (Type: EXPERIMENTAL): Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent~* ambulatory male and female patients 18 years of age or older~* summarised score of signs and symptoms of blepharitis of 15 or more at baseline~Exclusion Criteria:~* different ocular conditions~* different system conditions~* several concomitant medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posiformin 2 % (Type: ACTIVE_COMPARATOR): Eye ointment applied to the eye lid
- Placebo (Type: PLACEBO_COMPARATOR): corresponding vehicle, eye ointment applied to the eye lid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reasonably healthy men and women aged 50 to 75~Exclusion Criteria:~* History of abnormal bleeding, active bleeding or risk factors for bleeding~* History of thrombosis or risk factors for thrombosis~* History of adult asthma or use of inhaled medications

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Andexanet (Type: EXPERIMENTAL): Andexanet (antidote)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pycnogenol and Endothelial Function in Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of coronary artery disease (documented by coronary angiogram, nuclear imaging, positive stress test)~* Stable cardiovascular medication for at least 1 month~* Age ≥ 18 years of age at time of signing the informed consent~* Informed consent for participation in the study~Exclusion Criteria:~* Myocardial infarction, unstable angina, stroke (within 3 months before randomization)~* Thoracic or cardiac surgery and/or coronary intervention/revascularisation procedure (within 3 months before randomization)~* Uncontrolled symptomatic congestive heart failure (NHYA\> II) in the last 4 weeks prior to study~* Renal insufficiency (Creatinine Clearance \< 50ml/min)~* Ventricular tachyarrhythmias~* Poorly controlled hypertension, defined as resting blood pressure ≥ 160/100 mmHg~* Symptomatic hypotension~* Obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, untreated hypothyroidism or hyperthyroidism and adrenal insufficiency~* Severe uncorrected valvular disease or left ventricular outflow obstruction, which, in the opinion of the investigator, requires surgery~* Long acting nitrates~* Oral or intravenous steroids therapy~* Insulin - dependent diabetes mellitus~* Recipient of any major organ transplant (eg, lung, liver, heart) or renal replacement therapy~* Malignancy (unless healed or remission \> 5 years)~* Anaemia (Hb\< 10g/dl)~* Known to be human immunodeficiency virus (HIV) positive or active virus - hepatitis~* Alanine transaminase (ALT) or aspartate transaminase (AST) \> 3 times the upper limit of the normal range~* Known hypersensitivity to Pycnogenol®~* Alcohol, nicotine abuse or illicit drug abuse~* Pregnancy or breast-feeding, women with child - bearing potential without adequate contraception~* Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)~* Participation in another study within the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pycnogenol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To be included, patients must have diagnosis of Spasticity by IC10 criteria.~* We will enroll patients on current treatment for spasticity at the Spasticity outpatient clinic of HCPA, already in treatment with BTA or starting that treatment based on their doctors' decision, who are willing to participate in the trial by signing an informed consent form.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1-BTA Lanzhou/Allergan (Type: ACTIVE_COMPARATOR): Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
- 2. BTA Allergan/Lanzhou (Type: ACTIVE_COMPARATOR): Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients willing to participate with confirmed diagnosis of COPD~* 40 years of age or older~* having a 10 pack year smoking history~* able to perform serial pulmonary function tests~* able to use both a DPI and Respimat device~Exclusion Criteria:~Significant other disease~* clinically relevant abnormal hematology, chemistry, or urinalysis~* history of asthma~* diagnosis of thyrotoxicosis~* paroxysmal tachycardia related to beta agonists~* history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year~* active tuberculosis, cystic fibrosis, clinically evident bronchiectasis~* significant alcohol or drug use~* pulmonary resection~* taking oral beta adrenergics~* taking unstable oral steroids~* daytime oxygen~* enrolled in rehabilitation program~* enrolled in another study or taking investigational products~* pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control~* those who are not willing to comply with pulmonary medication washouts

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI1744 (Olodaterol) (Type: EXPERIMENTAL): Medium Dose once Daily
- BI 1744 (Olodaterol) (Type: EXPERIMENTAL): Low Dose once Daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once Daily
- Foradil (Type: ACTIVE_COMPARATOR): 12 mcg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria~* Patients who are aged 18 years or older at informed consent~* Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.~Exclusion Criteria:~* Patients who fall under a contraindication listed in the blonanserin (LONASEN) package insert~* Patients with Parkinson disease~* Patients who previously received blonanserin, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DSP-5423P Placebo (Type: PLACEBO_COMPARATOR): Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
- DSP-5423P 40mg (Type: EXPERIMENTAL): Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
- DSP-5423P 80mg (Type: EXPERIMENTAL): Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
- DSP-5423P Placebo-to-Flex (Type: EXPERIMENTAL): Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
- DSP-5423P Active-to-Flex (Type: EXPERIMENTAL): Percutaneous Subjects received DSP-5423P 40mg or 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient, male or female of any race, and at least 12 years of age. Female subjects of childbearing potential must have a negative urine pregnancy test result at baseline and practice a reliable method of contraception throughout the study.~* Mild to moderate, plaque-type psoriasis~* Target lesion on the trunk or extremities (excluding palms/soles, elbows, or knees) with a score of 2 or 3 for each of erythema, scaling and plaque thickness~* Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization Forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.~Exclusion Criteria:~* Female subjects who are pregnant (positive urine pregnancy test) breast feeding or who are of childbearing potential and not practicing a reliable method of birth control~* Known allergy to clobetasol propionate or other topical corticosteroids; or to any component of the investigational formulations~* Subjects who have not complied with the proper wash-out periods for prohibited medications~* Medical condition that in the opinion of the investigator, contraindicates the subject's participation in the clinical study~* Skin disease/disorder that might interfere with the study related diagnosis or evaluations~* Evidence of recent alcohol or drug abuse~* History of poor cooperation, non-compliance with medical treatment or unreliability

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clobetasol Propionate Foam (Type: EXPERIMENTAL): Topical foam formulation that includes clobetasol propionate (Steroid)
- Vehicle Foam (Type: PLACEBO_COMPARATOR): Vehicle foam is the same as the clobetasol propionate foam except it does not include the active drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* vitiligo and surface area involved of less than10% who are being followed in the outpatient dermatology clinics of King Abdullah University Hospital (KAUH)~* 6 weeks wash out period from previous treatments will be employed to eliminate any effect from such treatments~Exclusion Criteria:~* Skin dermatoses with Kobner phenomenon~* Lupus erythematous~* Pacemakers~* Hyper-photosensitivity~* Melanoma and non-melanoma skin cancers~* Drugs with photosensitizer side effect~* Radiotherapy~* Pregnancy (by principle, nno study available)~* Diseases that are contagious by contact

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus + excimer light (group A) (Type: ACTIVE_COMPARATOR): group A, will be treated by Tacrolimus 0.1% ointment twice daily and excimer light 308nm twice weekly (exciplex®)
- Tacrolimus (group B) (Type: ACTIVE_COMPARATOR): group B will start on Tacrolimus 0.1% ointment twice daily alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Riluzole in the Treatment of Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 18-65~* Meets DSM-IV criteria for Bipolar Disorder and is currently depressed~* Current score of \>/= 18 on the Hamilton Depression Scale~Exclusion Criteria:~* Active psychotic/manic symptoms~* Lifetime history of schizophrenia or obsessive compulsive disorder~* Clinically significant medical disease~* Women who are pregnant or lactating and women who are not using a medically accepted method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Riluzole (Type: EXPERIMENTAL): Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with thalassemia major, sickle cell disease (SCD), low or intermediate 1 (INT 1) risk myelodysplastic syndrome (MDS) or other anemias and transfusional hemosiderosis.~* Patients who were on, starting, or resuming treatment with Exjade.~* Patients who were \>2 years (i.e., 2 years of age or older).~Exclusion criteria:~* Serum creatinine above the upper limit of normal (ULN) for age.~* Alanine aminotransferase (ALT) \>2.5 times the ULN.-High risk intermediate-2 or high risk MDS or acute leukemia.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completed study P06107 and demonstrated acceptable degree of compliance with medication, visits and other study requirements~* Must be male or a female who is not of childbearing potential and is not sexually active or is using a medically accepted method of contraception; or female who is not pregnant, or not lactating.~* Must have a caregiver or responsible person living with the participant who agrees to provide support to ensure compliance with treatment, visits, and protocol procedures~Exclusion Criteria:~* Positive pregnancy test or intention to become pregnant during the study~* At imminent risk of self-harm or harm to others~* Under involuntary inpatient commitment~* Known serological evidence of human immunodeficiency virus (HIV) antibody

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Asenapine/Asenapine (Type: EXPERIMENTAL): Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
- Placebo/Asenapine (Type: EXPERIMENTAL): Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete